Biosimilars Industry Research Report 2025
Description
Summary
According to APO Research, the global Biosimilars market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Biosimilars include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars.
The report will help the Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Biosimilars Segment by Company
Teva Pharmaceutical
Samsung Biologics
Novartis
Merck KgaA
Mylan
Roche
Eli Lilly
Pfizer
Gan & Lee Pharmaceuticals
Biogen
Amgen
Stada Arzneimittel AG
Probiomed
JCR Pharmaceuticals
Gedeon Richter
Fresenius Kabi AG
Dr. Reddy's Laboratories
Coherus Bioscience
Chong Kun Dang
Celltrion
Boehringer Ingelheim
Biocon
Biocad
Apotex
Biosimilars Segment by Type
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
Biosimilars Segment by Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Others
Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Biosimilars market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Biosimilars include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars.
The report will help the Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Biosimilars Segment by Company
Teva Pharmaceutical
Samsung Biologics
Novartis
Merck KgaA
Mylan
Roche
Eli Lilly
Pfizer
Gan & Lee Pharmaceuticals
Biogen
Amgen
Stada Arzneimittel AG
Probiomed
JCR Pharmaceuticals
Gedeon Richter
Fresenius Kabi AG
Dr. Reddy's Laboratories
Coherus Bioscience
Chong Kun Dang
Celltrion
Boehringer Ingelheim
Biocon
Biocad
Apotex
Biosimilars Segment by Type
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
Biosimilars Segment by Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Others
Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
144 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Biosimilars Market Size (2020-2031)
- 2.2.2 Global Biosimilars Sales (2020-2031)
- 2.2.3 Global Biosimilars Market Average Price (2020-2031)
- 2.3 Biosimilars by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
- 2.3.3 Recombinant Glycosylated Proteins
- 2.4 Biosimilars by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Oncology
- 2.4.3 Blood Disorders
- 2.4.4 Growth Hormonal Deficiency
- 2.4.5 Chronic and Autoimmune Disorders
- 2.4.6 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Biosimilars Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Biosimilars Sales (k units) of Manufacturers (2020-2025)
- 3.3 Global Biosimilars Revenue of Manufacturers (2020-2025)
- 3.4 Global Biosimilars Average Price by Manufacturers (2020-2025)
- 3.5 Global Biosimilars Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Biosimilars, Product Type & Application
- 3.8 Global Manufacturers of Biosimilars, Established Date
- 3.9 Global Biosimilars Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical
- 4.1.1 Teva Pharmaceutical Company Information
- 4.1.2 Teva Pharmaceutical Business Overview
- 4.1.3 Teva Pharmaceutical Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Teva Pharmaceutical Biosimilars Product Portfolio
- 4.1.5 Teva Pharmaceutical Recent Developments
- 4.2 Samsung Biologics
- 4.2.1 Samsung Biologics Company Information
- 4.2.2 Samsung Biologics Business Overview
- 4.2.3 Samsung Biologics Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Samsung Biologics Biosimilars Product Portfolio
- 4.2.5 Samsung Biologics Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Novartis Biosimilars Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Merck KgaA
- 4.4.1 Merck KgaA Company Information
- 4.4.2 Merck KgaA Business Overview
- 4.4.3 Merck KgaA Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Merck KgaA Biosimilars Product Portfolio
- 4.4.5 Merck KgaA Recent Developments
- 4.5 Mylan
- 4.5.1 Mylan Company Information
- 4.5.2 Mylan Business Overview
- 4.5.3 Mylan Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Mylan Biosimilars Product Portfolio
- 4.5.5 Mylan Recent Developments
- 4.6 Roche
- 4.6.1 Roche Company Information
- 4.6.2 Roche Business Overview
- 4.6.3 Roche Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Roche Biosimilars Product Portfolio
- 4.6.5 Roche Recent Developments
- 4.7 Eli Lilly
- 4.7.1 Eli Lilly Company Information
- 4.7.2 Eli Lilly Business Overview
- 4.7.3 Eli Lilly Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Eli Lilly Biosimilars Product Portfolio
- 4.7.5 Eli Lilly Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Pfizer Biosimilars Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Gan & Lee Pharmaceuticals
- 4.9.1 Gan & Lee Pharmaceuticals Company Information
- 4.9.2 Gan & Lee Pharmaceuticals Business Overview
- 4.9.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
- 4.9.5 Gan & Lee Pharmaceuticals Recent Developments
- 4.10 Biogen
- 4.10.1 Biogen Company Information
- 4.10.2 Biogen Business Overview
- 4.10.3 Biogen Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Biogen Biosimilars Product Portfolio
- 4.10.5 Biogen Recent Developments
- 4.11 Amgen
- 4.11.1 Amgen Company Information
- 4.11.2 Amgen Business Overview
- 4.11.3 Amgen Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Amgen Biosimilars Product Portfolio
- 4.11.5 Amgen Recent Developments
- 4.12 Stada Arzneimittel AG
- 4.12.1 Stada Arzneimittel AG Company Information
- 4.12.2 Stada Arzneimittel AG Business Overview
- 4.12.3 Stada Arzneimittel AG Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Stada Arzneimittel AG Biosimilars Product Portfolio
- 4.12.5 Stada Arzneimittel AG Recent Developments
- 4.13 Probiomed
- 4.13.1 Probiomed Company Information
- 4.13.2 Probiomed Business Overview
- 4.13.3 Probiomed Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 Probiomed Biosimilars Product Portfolio
- 4.13.5 Probiomed Recent Developments
- 4.14 JCR Pharmaceuticals
- 4.14.1 JCR Pharmaceuticals Company Information
- 4.14.2 JCR Pharmaceuticals Business Overview
- 4.14.3 JCR Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 JCR Pharmaceuticals Biosimilars Product Portfolio
- 4.14.5 JCR Pharmaceuticals Recent Developments
- 4.15 Gedeon Richter
- 4.15.1 Gedeon Richter Company Information
- 4.15.2 Gedeon Richter Business Overview
- 4.15.3 Gedeon Richter Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 Gedeon Richter Biosimilars Product Portfolio
- 4.15.5 Gedeon Richter Recent Developments
- 4.16 Fresenius Kabi AG
- 4.16.1 Fresenius Kabi AG Company Information
- 4.16.2 Fresenius Kabi AG Business Overview
- 4.16.3 Fresenius Kabi AG Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.16.4 Fresenius Kabi AG Biosimilars Product Portfolio
- 4.16.5 Fresenius Kabi AG Recent Developments
- 4.17 Dr. Reddy's Laboratories
- 4.17.1 Dr. Reddy's Laboratories Company Information
- 4.17.2 Dr. Reddy's Laboratories Business Overview
- 4.17.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.17.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
- 4.17.5 Dr. Reddy's Laboratories Recent Developments
- 4.18 Coherus Bioscience
- 4.18.1 Coherus Bioscience Company Information
- 4.18.2 Coherus Bioscience Business Overview
- 4.18.3 Coherus Bioscience Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.18.4 Coherus Bioscience Biosimilars Product Portfolio
- 4.18.5 Coherus Bioscience Recent Developments
- 4.19 Chong Kun Dang
- 4.19.1 Chong Kun Dang Company Information
- 4.19.2 Chong Kun Dang Business Overview
- 4.19.3 Chong Kun Dang Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.19.4 Chong Kun Dang Biosimilars Product Portfolio
- 4.19.5 Chong Kun Dang Recent Developments
- 4.20 Celltrion
- 4.20.1 Celltrion Company Information
- 4.20.2 Celltrion Business Overview
- 4.20.3 Celltrion Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.20.4 Celltrion Biosimilars Product Portfolio
- 4.20.5 Celltrion Recent Developments
- 4.21 Boehringer Ingelheim
- 4.21.1 Boehringer Ingelheim Company Information
- 4.21.2 Boehringer Ingelheim Business Overview
- 4.21.3 Boehringer Ingelheim Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.21.4 Boehringer Ingelheim Biosimilars Product Portfolio
- 4.21.5 Boehringer Ingelheim Recent Developments
- 4.22 Biocon
- 4.22.1 Biocon Company Information
- 4.22.2 Biocon Business Overview
- 4.22.3 Biocon Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.22.4 Biocon Biosimilars Product Portfolio
- 4.22.5 Biocon Recent Developments
- 4.23 Biocad
- 4.23.1 Biocad Company Information
- 4.23.2 Biocad Business Overview
- 4.23.3 Biocad Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.23.4 Biocad Biosimilars Product Portfolio
- 4.23.5 Biocad Recent Developments
- 4.24 Apotex
- 4.24.1 Apotex Company Information
- 4.24.2 Apotex Business Overview
- 4.24.3 Apotex Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.24.4 Apotex Biosimilars Product Portfolio
- 4.24.5 Apotex Recent Developments
- 5 Global Biosimilars Market Scenario by Region
- 5.1 Global Biosimilars Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Biosimilars Sales by Region: 2020-2031
- 5.2.1 Global Biosimilars Sales by Region: 2020-2025
- 5.2.2 Global Biosimilars Sales by Region: 2026-2031
- 5.3 Global Biosimilars Revenue by Region: 2020-2031
- 5.3.1 Global Biosimilars Revenue by Region: 2020-2025
- 5.3.2 Global Biosimilars Revenue by Region: 2026-2031
- 5.4 North America Biosimilars Market Facts & Figures by Country
- 5.4.1 North America Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Biosimilars Sales by Country (2020-2031)
- 5.4.3 North America Biosimilars Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Biosimilars Market Facts & Figures by Country
- 5.5.1 Europe Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Biosimilars Sales by Country (2020-2031)
- 5.5.3 Europe Biosimilars Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Biosimilars Market Facts & Figures by Country
- 5.6.1 Asia Pacific Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Biosimilars Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Biosimilars Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Biosimilars Market Facts & Figures by Country
- 5.7.1 South America Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Biosimilars Sales by Country (2020-2031)
- 5.7.3 South America Biosimilars Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Biosimilars Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Biosimilars Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Biosimilars Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Biosimilars Sales by Type (2020-2031)
- 6.1.1 Global Biosimilars Sales by Type (2020-2031) & (k units)
- 6.1.2 Global Biosimilars Sales Market Share by Type (2020-2031)
- 6.2 Global Biosimilars Revenue by Type (2020-2031)
- 6.2.1 Global Biosimilars Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Biosimilars Revenue Market Share by Type (2020-2031)
- 6.3 Global Biosimilars Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Biosimilars Sales by Application (2020-2031)
- 7.1.1 Global Biosimilars Sales by Application (2020-2031) & (k units)
- 7.1.2 Global Biosimilars Sales Market Share by Application (2020-2031)
- 7.2 Global Biosimilars Revenue by Application (2020-2031)
- 7.2.1 Global Biosimilars Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Biosimilars Revenue Market Share by Application (2020-2031)
- 7.3 Global Biosimilars Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Biosimilars Value Chain Analysis
- 8.1.1 Biosimilars Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Biosimilars Production Mode & Process
- 8.2 Biosimilars Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Biosimilars Distributors
- 8.2.3 Biosimilars Customers
- 9 Global Biosimilars Analyzing Market Dynamics
- 9.1 Biosimilars Industry Trends
- 9.2 Biosimilars Industry Drivers
- 9.3 Biosimilars Industry Opportunities and Challenges
- 9.4 Biosimilars Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Biosimilars Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Biosimilars Sales (k units) of Manufacturers (2020-2025)
- Table 7. Global Biosimilars Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Biosimilars Revenue of Manufacturers (2020-2025)
- Table 9. Global Biosimilars Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Biosimilars Average Price (US$/unit) of Manufacturers (2020-2025)
- Table 11. Global Biosimilars Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Biosimilars, Product Type & Application
- Table 14. Global Biosimilars Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Teva Pharmaceutical Company Information
- Table 19. Teva Pharmaceutical Business Overview
- Table 20. Teva Pharmaceutical Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 21. Teva Pharmaceutical Biosimilars Product Portfolio
- Table 22. Teva Pharmaceutical Recent Developments
- Table 23. Samsung Biologics Company Information
- Table 24. Samsung Biologics Business Overview
- Table 25. Samsung Biologics Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 26. Samsung Biologics Biosimilars Product Portfolio
- Table 27. Samsung Biologics Recent Developments
- Table 28. Novartis Company Information
- Table 29. Novartis Business Overview
- Table 30. Novartis Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 31. Novartis Biosimilars Product Portfolio
- Table 32. Novartis Recent Developments
- Table 33. Merck KgaA Company Information
- Table 34. Merck KgaA Business Overview
- Table 35. Merck KgaA Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 36. Merck KgaA Biosimilars Product Portfolio
- Table 37. Merck KgaA Recent Developments
- Table 38. Mylan Company Information
- Table 39. Mylan Business Overview
- Table 40. Mylan Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 41. Mylan Biosimilars Product Portfolio
- Table 42. Mylan Recent Developments
- Table 43. Roche Company Information
- Table 44. Roche Business Overview
- Table 45. Roche Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 46. Roche Biosimilars Product Portfolio
- Table 47. Roche Recent Developments
- Table 48. Eli Lilly Company Information
- Table 49. Eli Lilly Business Overview
- Table 50. Eli Lilly Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 51. Eli Lilly Biosimilars Product Portfolio
- Table 52. Eli Lilly Recent Developments
- Table 53. Pfizer Company Information
- Table 54. Pfizer Business Overview
- Table 55. Pfizer Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 56. Pfizer Biosimilars Product Portfolio
- Table 57. Pfizer Recent Developments
- Table 58. Gan & Lee Pharmaceuticals Company Information
- Table 59. Gan & Lee Pharmaceuticals Business Overview
- Table 60. Gan & Lee Pharmaceuticals Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 61. Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
- Table 62. Gan & Lee Pharmaceuticals Recent Developments
- Table 63. Biogen Company Information
- Table 64. Biogen Business Overview
- Table 65. Biogen Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 66. Biogen Biosimilars Product Portfolio
- Table 67. Biogen Recent Developments
- Table 68. Amgen Company Information
- Table 69. Amgen Business Overview
- Table 70. Amgen Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 71. Amgen Biosimilars Product Portfolio
- Table 72. Amgen Recent Developments
- Table 73. Stada Arzneimittel AG Company Information
- Table 74. Stada Arzneimittel AG Business Overview
- Table 75. Stada Arzneimittel AG Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 76. Stada Arzneimittel AG Biosimilars Product Portfolio
- Table 77. Stada Arzneimittel AG Recent Developments
- Table 78. Probiomed Company Information
- Table 79. Probiomed Business Overview
- Table 80. Probiomed Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 81. Probiomed Biosimilars Product Portfolio
- Table 82. Probiomed Recent Developments
- Table 83. JCR Pharmaceuticals Company Information
- Table 84. JCR Pharmaceuticals Business Overview
- Table 85. JCR Pharmaceuticals Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 86. JCR Pharmaceuticals Biosimilars Product Portfolio
- Table 87. JCR Pharmaceuticals Recent Developments
- Table 88. Gedeon Richter Company Information
- Table 89. Gedeon Richter Business Overview
- Table 90. Gedeon Richter Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 91. Gedeon Richter Biosimilars Product Portfolio
- Table 92. Gedeon Richter Recent Developments
- Table 93. Fresenius Kabi AG Company Information
- Table 94. Fresenius Kabi AG Business Overview
- Table 95. Fresenius Kabi AG Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 96. Fresenius Kabi AG Biosimilars Product Portfolio
- Table 97. Fresenius Kabi AG Recent Developments
- Table 98. Dr. Reddy's Laboratories Company Information
- Table 99. Dr. Reddy's Laboratories Business Overview
- Table 100. Dr. Reddy's Laboratories Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 101. Dr. Reddy's Laboratories Biosimilars Product Portfolio
- Table 102. Dr. Reddy's Laboratories Recent Developments
- Table 103. Coherus Bioscience Company Information
- Table 104. Coherus Bioscience Business Overview
- Table 105. Coherus Bioscience Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 106. Coherus Bioscience Biosimilars Product Portfolio
- Table 107. Coherus Bioscience Recent Developments
- Table 108. Chong Kun Dang Company Information
- Table 109. Chong Kun Dang Business Overview
- Table 110. Chong Kun Dang Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 111. Chong Kun Dang Biosimilars Product Portfolio
- Table 112. Chong Kun Dang Recent Developments
- Table 113. Celltrion Company Information
- Table 114. Celltrion Business Overview
- Table 115. Celltrion Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 116. Celltrion Biosimilars Product Portfolio
- Table 117. Celltrion Recent Developments
- Table 118. Boehringer Ingelheim Company Information
- Table 119. Boehringer Ingelheim Business Overview
- Table 120. Boehringer Ingelheim Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 121. Boehringer Ingelheim Biosimilars Product Portfolio
- Table 122. Boehringer Ingelheim Recent Developments
- Table 123. Biocon Company Information
- Table 124. Biocon Business Overview
- Table 125. Biocon Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 126. Biocon Biosimilars Product Portfolio
- Table 127. Biocon Recent Developments
- Table 128. Biocad Company Information
- Table 129. Biocad Business Overview
- Table 130. Biocad Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 131. Biocad Biosimilars Product Portfolio
- Table 132. Biocad Recent Developments
- Table 133. Apotex Company Information
- Table 134. Apotex Business Overview
- Table 135. Apotex Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 136. Apotex Biosimilars Product Portfolio
- Table 137. Apotex Recent Developments
- Table 138. Global Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 139. Global Biosimilars Sales by Region (2020-2025) & (k units)
- Table 140. Global Biosimilars Sales Market Share by Region (2020-2025)
- Table 141. Global Biosimilars Sales by Region (2026-2031) & (k units)
- Table 142. Global Biosimilars Sales Market Share by Region (2026-2031)
- Table 143. Global Biosimilars Revenue by Region (2020-2025) & (US$ Million)
- Table 144. Global Biosimilars Revenue Market Share by Region (2020-2025)
- Table 145. Global Biosimilars Revenue by Region (2026-2031) & (US$ Million)
- Table 146. Global Biosimilars Revenue Market Share by Region (2026-2031)
- Table 147. North America Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 148. North America Biosimilars Sales by Country (2020-2025) & (k units)
- Table 149. North America Biosimilars Sales by Country (2026-2031) & (k units)
- Table 150. North America Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 151. North America Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 152. Europe Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 153. Europe Biosimilars Sales by Country (2020-2025) & (k units)
- Table 154. Europe Biosimilars Sales by Country (2026-2031) & (k units)
- Table 155. Europe Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 156. Europe Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 157. Asia Pacific Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 158. Asia Pacific Biosimilars Sales by Country (2020-2025) & (k units)
- Table 159. Asia Pacific Biosimilars Sales by Country (2026-2031) & (k units)
- Table 160. Asia Pacific Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 161. Asia Pacific Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 162. South America Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 163. South America Biosimilars Sales by Country (2020-2025) & (k units)
- Table 164. South America Biosimilars Sales by Country (2026-2031) & (k units)
- Table 165. South America Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 166. South America Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 167. Middle East and Africa Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 168. Middle East and Africa Biosimilars Sales by Country (2020-2025) & (k units)
- Table 169. Middle East and Africa Biosimilars Sales by Country (2026-2031) & (k units)
- Table 170. Middle East and Africa Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 171. Middle East and Africa Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 172. Global Biosimilars Sales by Type (2020-2025) & (k units)
- Table 173. Global Biosimilars Sales by Type (2026-2031) & (k units)
- Table 174. Global Biosimilars Sales Market Share by Type (2020-2025)
- Table 175. Global Biosimilars Sales Market Share by Type (2026-2031)
- Table 176. Global Biosimilars Revenue by Type (2020-2025) & (US$ Million)
- Table 177. Global Biosimilars Revenue by Type (2026-2031) & (US$ Million)
- Table 178. Global Biosimilars Revenue Market Share by Type (2020-2025)
- Table 179. Global Biosimilars Revenue Market Share by Type (2026-2031)
- Table 180. Global Biosimilars Price by Type (2020-2025) & (US$/unit)
- Table 181. Global Biosimilars Price by Type (2026-2031) & (US$/unit)
- Table 182. Global Biosimilars Sales by Application (2020-2025) & (k units)
- Table 183. Global Biosimilars Sales by Application (2026-2031) & (k units)
- Table 184. Global Biosimilars Sales Market Share by Application (2020-2025)
- Table 185. Global Biosimilars Sales Market Share by Application (2026-2031)
- Table 186. Global Biosimilars Revenue by Application (2020-2025) & (US$ Million)
- Table 187. Global Biosimilars Revenue by Application (2026-2031) & (US$ Million)
- Table 188. Global Biosimilars Revenue Market Share by Application (2020-2025)
- Table 189. Global Biosimilars Revenue Market Share by Application (2026-2031)
- Table 190. Global Biosimilars Price by Application (2020-2025) & (US$/unit)
- Table 191. Global Biosimilars Price by Application (2026-2031) & (US$/unit)
- Table 192. Key Raw Materials
- Table 193. Raw Materials Key Suppliers
- Table 194. Biosimilars Distributors List
- Table 195. Biosimilars Customers List
- Table 196. Biosimilars Industry Trends
- Table 197. Biosimilars Industry Drivers
- Table 198. Biosimilars Industry Restraints
- Table 199. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Biosimilars Product Image
- Figure 5. Global Biosimilars Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Biosimilars Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Biosimilars Sales (2020-2031) & (k units)
- Figure 8. Global Biosimilars Average Price (US$/unit) & (2020-2031)
- Figure 9. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Product Image
- Figure 10. Recombinant Glycosylated Proteins Product Image
- Figure 11. Oncology Product Image
- Figure 12. Blood Disorders Product Image
- Figure 13. Growth Hormonal Deficiency Product Image
- Figure 14. Chronic and Autoimmune Disorders Product Image
- Figure 15. Others Product Image
- Figure 16. Global Biosimilars Revenue Share by Manufacturers in 2024
- Figure 17. Global Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
- Figure 18. Global Top 5 and 10 Biosimilars Players Market Share by Revenue in 2024
- Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 20. Global Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 21. Global Biosimilars Sales by Region in 2024
- Figure 22. Global Biosimilars Revenue by Region in 2024
- Figure 23. North America Biosimilars Market Size by Country in 2024
- Figure 24. North America Biosimilars Sales Market Share by Country (2020-2031)
- Figure 25. North America Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 26. United States Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 27. Canada Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 28. Europe Biosimilars Market Size by Country in 2024
- Figure 29. Europe Biosimilars Sales Market Share by Country (2020-2031)
- Figure 30. Europe Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 31. Germany Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. France Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. U.K. Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. Italy Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. Netherlands Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Nordic Countries Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Asia Pacific Biosimilars Market Size by Country in 2024
- Figure 38. Asia Pacific Biosimilars Sales Market Share by Country (2020-2031)
- Figure 39. Asia Pacific Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 40. China Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 41. Japan Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 42. South Korea Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 43. India Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. Australia Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. China Taiwan Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. Southeast Asia Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. Southeast Asia Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. South America Biosimilars Market Size by Country in 2024
- Figure 49. South America Biosimilars Sales Market Share by Country (2020-2031)
- Figure 50. South America Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 51. Mexico Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 52. Brazil Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 53. Argentina Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 54. Colombia Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Middle East and Africa Biosimilars Market Size by Country in 2024
- Figure 56. Middle East and Africa Biosimilars Sales Market Share by Country (2020-2031)
- Figure 57. Middle East and Africa Biosimilars Reve
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
